Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Microcrystalline hydroxyapatite concentrate (MCHC) is a supplement derived from bovine bone that contains calcium, phosphate, collagen, and trace elements in a structure similar to human bone. Its use for supporting bone health, particularly in cases of osteoporosis and bone fractures, is based on the idea that it provides the raw materials necessary for bone repair and regeneration. There is some scientific evidence supporting its effectiveness: several small clinical trials and animal studies have demonstrated that MCHC supplementation can enhance bone mineral density and may positively influence bone healing. For example, some studies in postmenopausal women have shown improvements in bone density with MCHC compared to calcium carbonate or placebo. Additionally, the bioavailability of calcium from MCHC may be superior to other forms of calcium supplementation. However, direct evidence supporting the use of MCHC specifically to treat or speed the healing of broken bones in humans is limited, and most available research focuses on its preventive role in osteoporosis rather than acute fracture repair. As such, while the scientific rationale is plausible and some supporting data exist, the evidence base is not robust, and major medical guidelines do not specifically recommend MCHC for fracture treatment. More large-scale, well-controlled studies are needed to establish its efficacy for this indication.

More about microcrystalline hydroxyapatite concentrate (MCHC)
More about Broken Bones

Other ingredients used for Broken Bones

Other health conditions supported by microcrystalline hydroxyapatite concentrate (MCHC)

Products containing microcrystalline hydroxyapatite concentrate (MCHC)